2020
DOI: 10.1210/jendso/bvaa151
|View full text |Cite|
|
Sign up to set email alerts
|

X-Linked Hypophosphatemia: A New Era in Management

Abstract: X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive musculoskeletal disease that often causes pain and short stature, as well as decreased physical function, mobility, and quality of life. Hypophosphatemia in XLH is caused by loss of function mutations in PHEX gene resulting in excess levels of the phosphate regulating hormone fibroblast growth factor23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production. Historically, treatment options were lim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
72
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 42 publications
(76 citation statements)
references
References 70 publications
0
72
0
Order By: Relevance
“…Most of the patients have osteoarticular and muscle pain with weakness, and they frequently show fatigue that reduces exercise tolerance. Fractures are uncommon in pediatric patients with XLH, but osteomalacic fractures (pseudofractures) may affect older patients (8,14,15). Moreover, an unexpected increase in mortality in later life has been observed (16).…”
Section: Clinical Phenotypementioning
confidence: 99%
See 2 more Smart Citations
“…Most of the patients have osteoarticular and muscle pain with weakness, and they frequently show fatigue that reduces exercise tolerance. Fractures are uncommon in pediatric patients with XLH, but osteomalacic fractures (pseudofractures) may affect older patients (8,14,15). Moreover, an unexpected increase in mortality in later life has been observed (16).…”
Section: Clinical Phenotypementioning
confidence: 99%
“…The short biologic half-life of oral inorganic phosphate salts requires frequent administrations up to six times/day. Compliance with this treatment represents a major issue, mainly in infancy and puberty (8,15,(21)(22)(23)(24). Conventional treatment, which has been in place for approximately four decades, transiently increases serum phosphate concentration without notable changes in the maximum tubular reabsorption of phosphate normalized to the glomerular filtration rate (TmP/GFR).…”
Section: Medical Treatmentmentioning
confidence: 99%
See 1 more Smart Citation
“…These findings are consistent with the diffuse osteomalacia observed in Hyp mice (9,10,31) as well as in humans with XLH. (32,33) In WT mice, Matsuo and colleagues (34) were able to identify voids as large capillary loops lined with endothelial cells in the orbicular apophysis of the malleus during the first weeks of life. In the close vicinity of these capillaries, specific type I and type II collagen-producing hypermineralizing "auditory osteoblasts" were recently identified, (35) and new matrix production led to a rapid decrease of the diameter of the capillaries.…”
Section: Discussionmentioning
confidence: 99%
“…Because of the efficacy of genetic testing, recent emphasis has been placed on using gene panels to accelerate clinicians' diagnosis of phosphate‐wasting disorders. ( 11 , 12 , 13 )…”
Section: Introductionmentioning
confidence: 99%